Literature DB >> 7229226

Dose dependence of Hymenoptera venom immunotherapy.

D B Golden, A Kagey-Sobotka, M D Valentine, L M Lichtenstein.   

Abstract

The clinical and immunologic efficacy of venom immunotherapy up to 50 micrograms maintenance doses (half the recommended dose) was examined in 23 patients with anaphylactic sensitivity to insect stings and is compared with that in two groups of patients treated with the full 100-micrograms recommended dose. Four of the 19 patients challenged with insect stings had mild systemic reactions not requiring treatment. This 79% clinical efficacy is significantly less than the 96% to 100% success achieved with treatment to full 100-micrograms maintenance doses. The venom-specific IgG antibody response to the 50-micrograms dose reached a level significantly lower than observed with 100 micrograms doses. We conclude that the clinical and immunologic responses to venom immunotherapy are dose dependent and are more reliably complete at the recommended maintenance dose of 100 micrograms of each venom than at a dose of 50 micrograms.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7229226     DOI: 10.1016/0091-6749(81)90082-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

1.  Insect sting allergy. A study from 1980 to 2003 of patients who started treatment with venom immunotherapy between 1980 and 1998.

Authors:  Rolf Haye; Liv Kari Døsen
Journal:  Clin Mol Allergy       Date:  2005-08-19

2.  The sting.

Authors:  J H Day
Journal:  Can Fam Physician       Date:  1982-04       Impact factor: 3.275

3.  Venom immunotherapy for stinging insect allergy.

Authors:  D F Graft
Journal:  Clin Rev Allergy       Date:  1987-05

4.  Allergy to insect stings: a review.

Authors:  P W Ewan
Journal:  J R Soc Med       Date:  1985-03       Impact factor: 5.344

Review 5.  [Diagnosis and treatment of insect venom allergy. An important allergic issue for the ear, nose and throat specialist].

Authors:  O Pfaar; L Klimek; I Hansen; B A Stuck; K Hörmann
Journal:  HNO       Date:  2005-12       Impact factor: 1.284

6.  [Sting challenge: indications and execution].

Authors:  F Ruëff; B Przybilla
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

7.  Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.

Authors:  Marek L Kowalski; Ignacio Ansotegui; Werner Aberer; Mona Al-Ahmad; Mubeccel Akdis; Barbara K Ballmer-Weber; Kirsten Beyer; Miguel Blanca; Simon Brown; Chaweewan Bunnag; Arnaldo Capriles Hulett; Mariana Castells; Hiok Hee Chng; Frederic De Blay; Motohiro Ebisawa; Stanley Fineman; David B K Golden; Tari Haahtela; Michael Kaliner; Connie Katelaris; Bee Wah Lee; Joanna Makowska; Ulrich Muller; Joaquim Mullol; John Oppenheimer; Hae-Sim Park; James Parkerson; Giovanni Passalacqua; Ruby Pawankar; Harald Renz; Franziska Rueff; Mario Sanchez-Borges; Joaquin Sastre; Glenis Scadding; Scott Sicherer; Pongsakorn Tantilipikorn; James Tracy; Vera van Kempen; Barbara Bohle; G Walter Canonica; Luis Caraballo; Maximiliano Gomez; Komei Ito; Erika Jensen-Jarolim; Mark Larche; Giovanni Melioli; Lars K Poulsen; Rudolf Valenta; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2016-10-12       Impact factor: 4.084

Review 8.  Hymenoptera (apid and vespid) allergy: update in diagnosis and management.

Authors:  Gerald W Volcheck
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

9.  Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom.

Authors:  Johanna Stoevesandt; Bernd Hofmann; Johannes Hain; Andreas Kerstan; Axel Trautmann
Journal:  Allergy Asthma Clin Immunol       Date:  2013-09-02       Impact factor: 3.406

Review 10.  [Venom immunotherapy. Side effects and efficacy of treatment].

Authors:  F Ruëff; B Przybilla
Journal:  Hautarzt       Date:  2008-03       Impact factor: 1.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.